Novartis (NVS) Stock Rating Reaffirmed by Jefferies Financial Group

Novartis (NYSE:NVS)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Financial Group in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $105.00 price objective on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 19.14% from the stock’s current price. Jefferies Financial Group also issued estimates for Novartis’ Q4 2018 earnings at $1.41 EPS, FY2018 earnings at $5.31 EPS, FY2019 earnings at $5.60 EPS, FY2020 earnings at $6.25 EPS, FY2021 earnings at $6.92 EPS and FY2022 earnings at $7.36 EPS.

Other research analysts have also issued research reports about the stock. Citigroup upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 11th. Bank of America upgraded shares of Novartis from an “underperform” rating to a “buy” rating and set a $74.71 price objective on the stock in a research note on Monday, September 10th. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Tuesday, September 18th. Goldman Sachs Group upgraded shares of Novartis from a “neutral” rating to a “conviction-buy” rating in a research note on Friday, November 16th. Finally, ValuEngine upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research note on Wednesday, September 12th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $90.69.

NVS stock opened at $88.13 on Tuesday. Novartis has a 52-week low of $72.30 and a 52-week high of $94.19. The company has a current ratio of 1.20, a quick ratio of 0.96 and a debt-to-equity ratio of 0.29. The company has a market cap of $201.48 billion, a PE ratio of 18.32, a PEG ratio of 1.92 and a beta of 0.74.

Novartis (NYSE:NVS) last released its quarterly earnings results on Thursday, October 18th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.01. Novartis had a net margin of 25.98% and a return on equity of 15.81%. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $12.88 billion. During the same quarter in the previous year, the business earned $1.29 earnings per share. The firm’s revenue was up 2.9% compared to the same quarter last year. Equities research analysts anticipate that Novartis will post 5.2 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Howe & Rusling Inc. grew its position in Novartis by 50.9% in the third quarter. Howe & Rusling Inc. now owns 1,705 shares of the company’s stock worth $147,000 after acquiring an additional 575 shares in the last quarter. HPM Partners LLC grew its position in Novartis by 1.8% in the third quarter. HPM Partners LLC now owns 33,849 shares of the company’s stock worth $2,916,000 after acquiring an additional 587 shares in the last quarter. Palisade Asset Management LLC grew its position in Novartis by 2.7% in the third quarter. Palisade Asset Management LLC now owns 22,117 shares of the company’s stock worth $1,906,000 after acquiring an additional 588 shares in the last quarter. Ferguson Wellman Capital Management Inc. grew its position in Novartis by 9.2% in the third quarter. Ferguson Wellman Capital Management Inc. now owns 7,000 shares of the company’s stock worth $603,000 after acquiring an additional 590 shares in the last quarter. Finally, LeJeune Puetz Investment Counsel LLC grew its position in Novartis by 11.3% in the third quarter. LeJeune Puetz Investment Counsel LLC now owns 5,925 shares of the company’s stock worth $510,000 after acquiring an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

See Also: Risk Tolerance

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply